Treatment Outcomes of Sunitinib Treatment in Advanced Renal Cell Carcinoma Patients: A Single Cancer Center Experience in Korea
1
조회
0
다운로드
8
인용
0
참고문헌
키워드
초록
Purpose : The retrospective study was performed to assess the efficacy and toxicity profiles of sunitinib in Korean patients with metastatic renal cell carcinoma (RCC). Materials and Methods : Between January 2005 and December 2008, 76 Korean patients with recurrent/metastatic RCC who received sunitinib were retrospectively reviewed. The primary end point was progression-free survival and the secondary end points were overall survival and response rate. We also assessed the toxicities associated with sunitinib treatment. Results : Of the 76 patients, 69 (90.1%) were diagnosed with clear cell RCC. The median progressionfree survival and overall survival were 7.2 and 22.8 months, respectively in overall patients. Sixty-two patients (81.6%) received 50 mg 4 week and 2 week off schedule, and 14 patients (18.4%) received 37.5 mg daily on a daily continuous schedule. The objective response rate and disease control rate were 27.6% and 84.2%, respectively. A dose reduction or reduction in dose due to adverse events occurred in 76% of the patients, whereas 11% of the patients had discontinued treatment. Other common laboratory abnormalities were increased serum creatinine (75.6%), elevated alanine aminotransferase (71.0%), neutropenia (61.8%), anemia (69.7%), and increased aspartate aminotrasferase (53.3%). Grade 3/4 toxicities occurred as follows: thrombocytopenia (38.2%), fatigue (10.5%), stomatitis (10.5%), and hand-foot syndrome (9.2%). Conclusion : Our results indicate that sunitinib treatment is effective and tolerable for ecurrent/metastatic RCC patients in Korea. Further studies with prognostic or biochemical factors are needed to clarify the different toxicity profiles of this study.
Abstract
Purpose : The retrospective study was performed to assess the efficacy and toxicity profiles of sunitinib in Korean patients with metastatic renal cell carcinoma (RCC). Materials and Methods : Between January 2005 and December 2008, 76 Korean patients with recurrent/metastatic RCC who received sunitinib were retrospectively reviewed. The primary end point was progression-free survival and the secondary end points were overall survival and response rate. We also assessed the toxicities associated with sunitinib treatment. Results : Of the 76 patients, 69 (90.1%) were diagnosed with clear cell RCC. The median progressionfree survival and overall survival were 7.2 and 22.8 months, respectively in overall patients. Sixty-two patients (81.6%) received 50 mg 4 week and 2 week off schedule, and 14 patients (18.4%) received 37.5 mg daily on a daily continuous schedule. The objective response rate and disease control rate were 27.6% and 84.2%, respectively. A dose reduction or reduction in dose due to adverse events occurred in 76% of the patients, whereas 11% of the patients had discontinued treatment. Other common laboratory abnormalities were increased serum creatinine (75.6%), elevated alanine aminotransferase (71.0%), neutropenia (61.8%), anemia (69.7%), and increased aspartate aminotrasferase (53.3%). Grade 3/4 toxicities occurred as follows: thrombocytopenia (38.2%), fatigue (10.5%), stomatitis (10.5%), and hand-foot syndrome (9.2%). Conclusion : Our results indicate that sunitinib treatment is effective and tolerable for ecurrent/metastatic RCC patients in Korea. Further studies with prognostic or biochemical factors are needed to clarify the different toxicity profiles of this study.
참고문헌 (16)
- Kamangar F, "Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world", J Clin Oncol, 24, pp.2137~2150 (2006)
- Jemal A, "Cancer statistics, 2005", CA Cancer J Clin, 55, pp.10~30 (2005)
- Janzen NK, "Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease", Urol Clin North Am, 30, pp.843~852 (2003)
- Chow LQ, "Sunitinib: from rational design to clinical efficacy", J Clin Oncol, 25, pp.884~896 (2007)
- Abrams TJ, "SU11248 Inhibits KIT and platelet-derived growth factor receptor β‚ in preclinical models of human small cell lung cancer", Mol Cancer Ther, 2, pp.471~478 (2003)
- Gnarra JR, "Mutations of the VHL tumour suppressor gene in renal carcinoma", Nat Genet, 7, pp.85~90 (1994)
- Iliopoulos O, "Negative regulation of hypoxiainducible genes by the von Hippel-Lindau protein", Proc Natl Acad Sci USA, 93, pp.10595~10599 (1996)
- Motzer RJ, "Sunitinib versus interferon α in metastatic renal-cell carcinoma", N Engl J Med, 356, pp.115~124 (2007)
- Motzer RJ, "Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma", J Clin Oncol, 22, pp.454~463 (2004)
- Therasse P, "New guidelines to evaluate the response to treatment in solid tumors", J Natl Cancer Inst, 92, pp.205~216 (2000)
- 최문기, "TTP-HUS Associated with Sunitinib", Cancer Research and Treatment, 40(4), pp.211~213 (2008), 대한암학회
- Motzer RJ, "Sunitinib in patients with metastatic renal cell carcinoma", JAMA, 295, pp.2516~2524 (2006)
- Uemura H, "A phase II study of the efficacy and safety of sunitinib in treatment-naive and pretreated Japanese patients (pts) with metastatic renal cell carcinoma (mRCC)", J Clin Oncol, 26, pp.15S~ (2008)
- Law CC, "Toxicity profile and efficacy of oral capecitabine as adjuvant chemotherapy for Chinese patients with stage III colon cancer", Dis Colon Rectum, 50, pp.2180~2187 (2007)
- Yen-Revollo JL, "Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines?", Clin Cancer Res, 14, pp.8~13 (2008)
- Saif MW, "Atypical hand-and-foot syndrome in an African American patient treated with capecitabine with normal DPD activity: Is there an ethnic disparity?", Cutan Ocul Toxicol, 27, pp.311~315 (2008)